Trial Profile
A 2-part Study to Investigate the Dose-ranging Pharmacokinetics and Tolerability, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Drug Resistant Epilepsy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Jan 2020
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- 24 Jan 2020 Status changed from active, no longer recruiting to completed.
- 17 Jul 2018 Planned End Date changed from 1 Dec 2018 to 1 Apr 2019.
- 17 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jan 2019.